Last $17.85 USD
Change Today +0.60 / 3.48%
Volume 306.6K
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

angiodynamics inc (ANGO) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/10/14 - $19.00
52 Week Low
04/15/14 - $13.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGIODYNAMICS INC (ANGO)

angiodynamics inc (ANGO) Related Businessweek News

No Related Businessweek News Found

angiodynamics inc (ANGO) Details

AngioDynamics, Inc. designs, manufactures, and sells medical, surgical, and diagnostic devices. The company offers manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; and venous products, including laser system products used in endovascular laser procedures to treat superficial venous diseases, as well as sclerosing drugs that are used in the treatment of small uncomplicated varicose veins of the lower extremities. It also provides angiographic catheters and guidewires used during peripheral vascular interventional procedures; venous drainage cannula intended for use as a venous drainage cannula during extracorporeal bypass and cardiopulmonary bypass circuit intended for use in procedures requiring extracorporeal circulatory support; and drainage products that drain abscesses and other fluid pockets. In addition, the company offers thrombolytic catheters that are used to deliver thrombolytic agents; micro access sets for minimally-invasive procedures; dialysis catheters that provide short and long-term vascular access for dialysis patients; and peripherally inserted central catheters, implantable ports, and central venous catheters. Further, it provides radiofrequency ablation products, soft tissue surgical ablation products, and microwave ablation products. The company markets and sells its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly and through distributors in the United States and internationally. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

1,300 Employees
Last Reported Date: 08/14/14
Founded in 1988

angiodynamics inc (ANGO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $873.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $367.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $308.3K
Senior Vice President of Global Franchise, On...
Total Annual Compensation: $276.8K
Senior Vice President of Administration
Total Annual Compensation: $291.6K
Compensation as of Fiscal Year 2014.

angiodynamics inc (ANGO) Key Developments

AngioDynamics Inc. Announces Restatement of Unaudited Consolidated Earnings Results for the First Quarter Ended August 31, 2014

AngioDynamics Inc. announced restatement of unaudited consolidated earnings results for the first quarter ended August 31, 2014. For the period, the company reported net sales of $87,331,000 an increase of 4% compared with last year's first quarter net sales of $83,644,000. The company's net income was at $470,000 or $0.01 on a per share basis, compared to a net loss of $373,000 or $0.01 per share, a year ago. Operating income was at $3,242,000 against $1,402,000 reported last year. Income before income taxes was at $1,418,000 against a loss of $563,000 reported last year. Adjusted net income was $5,650,000 or $0.16 per share against $3,988,000 or $0.11 per share a year ago. First quarter EBITDA was $9,927,000, or $0.28 per share, compared to $8,149,000 or $0.23 per share, in the year ago period. Adjusted EBITDA was $14,412,000 or $0.40 per share, compared to $12,036,000 or $0.34 per share, in the year ago comparable period. Net cash provided by operating activities was at $5,352,000 against $7,300,000 reported last year. Additions to property, plant and equipment were at $5,104,000 against $2,903,000 reported last year. The company determined that financial management had incorrectly accounted for certain asset, liability and income statement balances, beginning in 2011. The immaterial error corrections identified were primarily related to failure to recognize the expense associated with prepaid and other assets in accordance with the underlying contractual terms (cumulative impact of approximately $1.2 million) and depreciation expense (cumulative impact of approximately $0.4 million), and other individually immaterial items.

AngioDynamics Announces Approval to Amendment to its Amended and Restated Certificate of Incorporation

AngioDynamics announced that its shareholders at its AGM, held on October 28, 2014, approved the proposal to approve an amendment to the its Amended and Restated Certificate of Incorporation.

AngioDynamics Inc.(NasdaqGS:ANGO) added to S&P 1000 Index

AngioDynamics Inc.(NasdaqGS:ANGO) added to S&P 1000 Index


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANGO:US $17.85 USD +0.60

ANGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aerovironment Inc $28.24 USD -2.44
CTS Corp $17.74 USD -0.11
LMI Aerospace Inc $14.19 USD +0.01
Micrel Inc $13.01 USD +0.34
Raven Industries Inc $23.01 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation ANGO Industry Range
Price/Earnings 100.0x
Price/Sales 1.7x
Price/Book 1.1x
Price/Cash Flow 29.8x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGIODYNAMICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at